Related Experiment Video
Updated: Jul 6, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Targeted therapies for cancer of the gallbladder
1Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Purpose Of Review:
Adenocarcinomas of the gallbladder are uncommon, aggressive tumors with poor survival. This review summarizes advances in understanding the biology of gallbladder cancer.
Recent Findings:
Published response rates of adenocarcinomas of the gallbladder to chemotherapy are less than 30% and no survival benefit has been demonstrated from palliative systemic therapy. New information on the molecular carcinogenic mechanisms of these malignancies, combined with findings from animal models, may lead to improved treatment for patients.
Summary:
Improved understanding of the molecular carcinogenesis of adenocarcinomas of the gallbladder, coupled with the availability of novel molecularly 'targeted' chemotherapeutic agents, may improve outcome for patients.
Insights
Gallbladder cancer is aggressive with poor outcomes. Advances in understanding its molecular biology and targeted therapies offer hope for improved patient treatment and survival.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Gallbladder adenocarcinoma is a rare and aggressive malignancy.
- These cancers are associated with a poor prognosis and limited treatment options.
Purpose of the Study:
- To review recent advancements in understanding gallbladder cancer biology.
- To explore potential new therapeutic strategies based on molecular insights.
Main Methods:
- Literature review of published studies on gallbladder cancer.
- Analysis of molecular mechanisms and findings from preclinical models.
Main Results:
- Chemotherapy response rates for gallbladder adenocarcinoma are below 30%.
- Palliative systemic therapy has not shown a significant survival benefit.
- Emerging data highlight key molecular carcinogenic pathways.
Conclusions:
- Enhanced understanding of gallbladder cancer's molecular carcinogenesis is crucial.
- Novel molecularly targeted agents hold promise for improving patient outcomes.
- Future research should focus on translating molecular discoveries into effective treatments.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...